The Online Investor
Stock Splits
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Stock Splits

By The Online Investor Staff, updated Sun., Feb. 18, 4:32 PM

Slide #9. RXi Pharmaceuticals Corporation (NASDAQ:RXII) 1 for 10 Reverse Split

Announced: 1/5/2018
Stock Split: 1 for 10
Record Date: 1/8/2018
Pay Date: 1/8/2018
RXII Optionable?: No

RXi Pharmaceuticals is a clinical-stage company developing therapeutics based on its self-delivering RNAi (sd-rxRNA®) platform and Samcyprone™, a topical immunomodulator. Co.'s clinical development programs include RXI-109, an sd-rxRNA for the treatment of dermal and ocular scarring, and Samcyprone™, for the treatment of warts. Co.'s development programs also include cell-based cancer immunotherapy. Co.'s RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its topical immunotherapy agent, Samcyprone™, treats diseases by inducing, enhancing or suppressing an immune response in the skin.
RXII Detailed Information Page & Split History »

Company Name:  RXi Pharmaceuticals Corp (New)
Website:  www.rxipharma.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding RXII:  1
Total Market Value Held by ETFs:  $1282
Total Market Capitalization:  $7.00M
% of Market Cap. Held by ETFs:  0.02%

Open the RXII Page at The Online Investor (in a new window) »

February 18, 2018    4:32 PM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
85th percentile
(ranked higher than approx. 85% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Stock Splits | www.TheOnlineInvestor.com | Copyright © 1998 - 2018, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.